Last updated: 2026-09-06 14:23:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
OnKure Therapeutics, Inc. (OKUR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.57, with a market capitalization of $143.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.23 to $5.38. This page covers its latest market performance, valuation, price trends and company information.
$143.36M | |
$3.53 | |
$20.00 | |
$1.70 | |
$3.56 | |
157.37K | |
-- | |
-- | |
$5.38 | |
$2.23 | |
-- | |
-- |
OnKure Therapeutics, Inc. (OKUR) last closed at $3.56 as of 2026-09-04 23:31:00, unchanged from the previous close of $3.56.
During the latest regular trading session, OKUR traded between $1.70 and $20.00, with a volume of 157.37K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, OnKure Therapeutics, Inc. (OKUR) moved from $3.80 to $3.57, representing a decline of 6.05% ($0.23).
The stock traded between $3.52 and $3.62 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 178.48 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 42.5%
OKUR is currently trading at $3.57, placing it 42.5% of the way from its 52-week low of $2.23 to its 52-week high of $5.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 45 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OnKure Therapeutics, Inc. (OKUR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.